Posted in Constellation in the News, Newsroom
Mark A. Goldsmith, M.D., Ph.D., to Serve as Executive Chairman of the Board of Directors CAMBRIDGE, Mass. – March 27, 2012 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced the appointment of Keith E. Dionne, Ph.D., to the role of president and chief executive officer to succeed Mark [...]
Read more »
Posted in Constellation in the News, Newsroom
CAMBRIDGE, Mass. – January 17, 2012 – Constellation Pharmaceuticals, Inc., today announced that it has entered into a major strategic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to launch a broad collaboration based on the science of epigenetics and chromatin biology to discover and develop innovative treatments for [...]
Read more »
Posted in Constellation in the News, Newsroom
Targeting Chromatin Adaptors to Suppress MYC, a Gene Dysregulated in Wide Range of Malignancies, Represents Promising Therapeutic Approach in Oncology CAMBRIDGE, Mass. – September 26, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced the publication of a paper in the Proceedings of the National Academy of [...]
Read more »
Posted in Constellation in the News, Newsroom
CAMBRIDGE, Mass. – June 6, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life [...]
Read more »
Posted in Constellation in the News
- Dr. Michael Cooper Appointed Chief Medical Officer - Dr. Steven Paul Elected to Board of Directors CAMBRIDGE, Mass. – February 1, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the expansion of its leadership team with the [...]
Read more »
Posted in Constellation in the News, Newsroom
MMRF Biotech Investment Awards Provide Funding to Industry to Advance Myeloma Therapies NORWALK, Conn. – January 6, 2011 – The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, [...]
Read more »
Posted in Constellation in the News, Newsroom
-Accomplished Executive Brings Broad Drug Discovery and Development Experience- CAMBRIDGE, MA – January 4, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the appointment of Dr. James E. Audia as Chief Scientific Officer. Audia joins Constellation following a [...]
Read more »
Posted in Newsroom
Epigenetics was spotlighted in the January issue of Time Magazine. Read the article: Why Your DNA Isn't Your Destiny
Read more »
Posted in Uncategorized
Environmental factors can alter the way our genes are expressed, making even identical twins different. Aired July 24, 2007 on PBS. Click the image to watch the full episode
Read more »
Posted in Constellation in the News, Newsroom
-Proceeds to Broaden Leading Epigenetics Product Engine and Advance Pipeline towards the Clinic- CAMBRIDGE, Mass. – June 2, 2010 – Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has raised $22 million in a Series B financing round. [...]
Read more »
